Clinical trials: Stage I Skin Cancer
Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT01100489
- Testing
- external beam radiation therapy, questionnaire administration, therapeutic conventional surgery
- Where
- 3 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms, Breast Diseases
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast cancer patients.
- Trial name
- NCT03304080
- Testing
- Anastrozole, Palbociclib, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement…
- Conditions
- Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage I Mycosis Fungoides, Stage II Mycosis Fungoides
- Trial name
- NCT02702310
- Testing
- Quality-of-Life Assessment, Objective Grading of Skin Findings
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Gastric Cancer, Metastatic Breast Cancer
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
This is a phase I, open-label, non-randomized, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of autologous p95HER2.CAR-TECH2Me T cells in patients with…
- Conditions
- Metastatic Gastric Cancer, Metastatic Breast Cancer, Endometrial Cancer Metastatic
- Trial name
- Catherine (NCT07593820)
- Testing
- p95HER2.CAR-TECH2Me
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Melanoma
Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response
The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body.
- Trial name
- NCT00680589
- Testing
- injection of mouse TYRP2 DNA
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07721259
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Advanced Cancer, Cervical Cancer
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
This is a multi-centre Phase I dose finding and proof-of-concept study of the combination of ASTX660 together with Pembrolizumab with expansion cohorts testing preliminary efficacy in immune-refractory cancers, triple negative…
- Conditions
- Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
- Trial name
- ASTEROID (NCT05082259)
- Testing
- ASTX660, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Solid Tumor, Extensive-stage Small-cell Lung Cancer
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
An open-label, two-part Phase I/Ib study of RP12146 in adult patients with locally advanced or metastatic solid tumors. The first part (Part 1) is a Phase I dose-escalation, 3+3 design, open-label, MTD determination study and…
- Conditions
- Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT05002868
- Testing
- RP12146
- Where
- 6 sites in Czechia, Poland
- Volunteers
- 23 people
- Sponsor
- Rhizen Pharmaceuticals SA
Medical Oncology
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5…
- Trial name
- NCT02366949
- Testing
- BAY1217389, Paclitaxel
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 75 people
- Sponsor
- Bayer
Peripheral Neuropathy, Stage I Breast Cancer AJCC v7
Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer
This clinical trial studies how well the sensorimotor rehabilitation program works in improving quality of life in patients with early stage breast cancer.
- Conditions
- Peripheral Neuropathy, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT03568526
- Testing
- Educational Intervention, Exercise Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT01989585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 49 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Endometrial Cancer
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen.
- Trial name
- NCT00002920
- Testing
- medroxyprogesterone, tamoxifen citrate, adjuvant therapy
- Where
- 122 sites in United States
- Volunteers
- 313 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
The primary goal is to determine the maximum tolerated dose (MTD) of the combination of T-DM1 and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously treated with taxanes and…
- Trial name
- THELMA (NCT02562378)
- Testing
- Trastuzumab and non-pegylated liposomal doxorubicin
- Where
- 4 sites in France, Spain
- Volunteers
- 15 people
- Sponsor
- MedSIR
Melanoma (Skin)
Gene Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00005943
- Testing
- aldesleukin, staphylococcal enterotoxin B
- Where
- United States
- Sponsor
- University of Colorado, Denver
Breast Cancer
Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer
The current standard of care for stage I-III HER2-positive breast cancer is adjuvant chemotherapy combined with 1 year of adjuvant trastuzumab.
- Trial name
- NCT02396108
- Testing
- Paclitaxel + Carboplatin + ASLAN001
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Metastatic Breast Cancer, Recurrent Breast Cancer
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
- Trial name
- BOCIS (NCT06900647)
- Testing
- Bortezomib (B), Cisplatin (CDDP)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
This is a research study to evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer.
- Trial name
- DIGNITY (NCT00826085)
- Testing
- ThermoDox in combination with Microwave Hyperthermia (heat)
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Imunon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.